• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

MGC Pharmaceuticals Share Price Pushes Up (ASX:MXC)

Like 0

By Carl Wittkopp, Wednesday, 07 October 2020

At the time of writing, shares of MGC Pharmaceuticals Ltd [ASX:MXC] are up 4.55% to trade at 2.3 cents. The cannabinoid-based pharmaceuticals company recently announced the launch of a new app: CannEpil...

At the time of writing, shares of MGC Pharmaceuticals Ltd [ASX:MXC] are up 4.55% to trade at 2.3 cents.

The cannabinoid-based pharmaceuticals company recently announced the launch of a new app: CannEpil.

ASX MXC Share Price - MGC Pharmaceuticals

Source: Optuma

What’s happening at MGC Pharmaceuticals?

MGC Pharmaceuticals labels its strategy ‘Nature to Medicine’.

Specifically, this strategy is based around the ‘development of drug delivery systems for cannabinoid-based products for cancer using nanotechnology targeting the CB2 receptors to control angiogenesis and inflammation.’

Today, MGC Pharmaceuticals in conjunction with their collaboration partner Royal Melbourne Institute of Technology (RMIT) have launched an app — CannEpil.

The app aims to provide access to the International Library of Cannabinoids to medical professionals. Along with collecting patient data — whilst under the supervision of a medicinal practitioner — with the goal of further evaluating the usage, dosage, and efficacy of CannEpilTM as a treatment.

The usage of cannabinoids is expanding rapidly in mainstream medical usage, with the global market expected to reach $44 billion by 2024.

With this in mind, an app that can be globally used and give access to the growing body of information and learnings could prove valuable to the medical community and MGC Pharmaceuticals.

Where to from here for MGC Pharmaceuticals?

At present the company holds a market cap of $36.1 million, and with the expected growth in the cannabinoid market, the company could be able to reverse the slide if they get more products to market.

MXC Share Price Chart 2

 

Source: Optuma

The MXC share price has moved sideways over the last month or so before popping up to its current level. If the increase can continue, then the levels of 2.5 and 3 cents may provide future resistance.

Should the price decline, then the level of 2 cents may be enough to halt a further fall.

Regards,

Carl Wittkopp,
For Money Morning

PS: Four Well-Positioned Small-Cap Stocks: These innovative Aussie companies are well placed to capitalise on post-lockdown megatrends. Click here to learn more.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Carl Wittkopp

Carl’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • America on a War Footing: Implications as US Mineral Strategy Turns to Africa
    By James Cooper

    Geologist James Cooper examines the potential implications of America’s heavy focus on West Africa. Why is the US becoming deeply involved here? And what could the consequences be?

  • The biggest quarter on record for this share
    By Callum Newman

    We can see why the stock market didn’t react much to the RBA holding rates steady last meeting. Everyone expects rates to go down. It’s just a question of when. Fixed rate loans, and refinancings, are withering away as the market positions for more rate cuts. This is what you and I want to see as investors…

  • The US$2 Trillion Stablecoin Tsunami
    By Charlie Ormond

    These developments could transform the US$250 billion stablecoin market into a US$2 trillion juggernaut within years.

Primary Sidebar

Latest Articles

  • America on a War Footing: Implications as US Mineral Strategy Turns to Africa
  • The biggest quarter on record for this share
  • The US$2 Trillion Stablecoin Tsunami
  • Trump Sparks Rare Earth Rally
  • Copper Breaks Out: Are You Positioned?

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988